Duan Suyan, Chen Si, Lu Fang, Zhou Meng, Jiang Ling, Chen Chen, Geng Luhan, Sun Rui, Xu Yili, Huang Zhimin, Zhang Chengning, Zhang Bo, Mao Huijuan, Xing Changying, Yuan Yanggang
Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing, China.
Front Nutr. 2023 Apr 25;10:1171216. doi: 10.3389/fnut.2023.1171216. eCollection 2023.
Primary membranous nephropathy (PMN) is an immune-related disease with increased morbidity and the most common cause of adult nephrotic syndrome (NS). The serum 25-hydroxyvitamin D [25(OH)D)], a biomarker of vitamin D (VD) status, tends to decline in patients with kidney disease. However, the relationship between 25(OH)D and PMN is still unclear. Therefore, this study aims to clarify the association between 25(OH)D and disease severity and therapy response of PMN.
A total of 490 participants diagnosed with PMN by biopsy from January 2017 to April 2022 were recruited at the First Affiliated Hospital of Nanjing Medical University. The correlations between baseline 25(OH)D and manifestations of nephrotic syndrome (NS) or seropositivity of anti-PLA2R Ab were confirmed by univariate and multivariate logistic analyses. Spearman's correlations were used to examine the associations between baseline 25(OH)D and other clinical parameters. In the follow-up cohort, Kaplan-Meier analysis was used to assess remission outcomes among groups with low, medium, and high levels of 25(OH)D. Furthermore, the independent risk factors for non-remission (NR) were explored by COX regression analysis.
At baseline, 25(OH)D was negatively related to 24-h urinary protein and serum anti-PLA2R Ab. The lower level of baseline 25(OH)D was associated with an increased risk for the incidence of NS in PMN (model 2, OR 6.8, 95% CI 4.4, 10.7, < 0.001) and seropositivity of anti-PLA2R Ab (model 2, OR 2.4, 95% CI 1.6, 3.7, < 0.001). Furthermore, the lower level of 25(OH)D during follow-up was demonstrated as an independent risk factor for NR even after adjusting age, gender, MBP, 24 h UP, serum anti-PLA2R Ab, serum albumin, and serum C3 [25(OH)D (39.2-62.3 nmol/L): HR 4.90, 95% CI 1.02, 23.53 = 0.047; 25(OH)D < 39.2 nmol/L: HR 17.52, 95% CI 4.04, 76.03 < 0.001); vs. 25(OH)D ≥ 62.3 nmol/L]. The Kaplan-Meier survival analysis also demonstrated that the higher level of follow-up 25(OH)D had a higher possibility of remission than the lower one (log-rank test, < 0.001).
Baseline 25(OH)D was significantly correlated with nephrotic proteinuria and seropositivity of anti-PLA2R Ab in PMN. As an independent risk factor for NR, a low level of 25(OH)D during follow-up might serve as a prognostic tool for sensitively identifying cases with a high probability of poor treatment response.
原发性膜性肾病(PMN)是一种发病率上升的免疫相关疾病,也是成人肾病综合征(NS)最常见的病因。血清25-羟基维生素D [25(OH)D] 作为维生素D(VD)状态的生物标志物,在肾病患者中往往会下降。然而,25(OH)D与PMN之间的关系仍不清楚。因此,本研究旨在阐明25(OH)D与PMN疾病严重程度及治疗反应之间的关联。
2017年1月至2022年4月期间,南京医科大学第一附属医院共招募了490例经活检确诊为PMN的参与者。通过单因素和多因素逻辑回归分析确定基线25(OH)D与肾病综合征(NS)表现或抗PLA2R抗体血清阳性之间的相关性。采用Spearman相关性分析基线25(OH)D与其他临床参数之间的关联。在随访队列中,采用Kaplan-Meier分析评估25(OH)D水平低、中、高组的缓解结局。此外,通过COX回归分析探索未缓解(NR)的独立危险因素。
在基线时,25(OH)D与24小时尿蛋白及血清抗PLA2R抗体呈负相关。较低的基线25(OH)D水平与PMN中NS发病风险增加(模型2,OR 6.8,95%CI 4.4,10.7,P<0.001)及抗PLA2R抗体血清阳性相关(模型2,OR 2.4,95%CI 1.6,3.7,P<0.001)。此外,随访期间较低的25(OH)D水平即使在调整年龄、性别、MBP、24小时UP、血清抗PLA2R抗体、血清白蛋白和血清C3后仍被证明是NR的独立危险因素[25(OH)D(39.2 - 62.3 nmol/L):HR 4.90,95%CI 1.02,23.53,P = 0.047;25(OH)D < 39.2 nmol/L:HR 17.52,95%CI 4.04,76.03,P<0.001);vs. 25(OH)D≥62.3 nmol/L]。Kaplan-Meier生存分析还表明,随访期间较高的25(OH)D水平比低水平有更高的缓解可能性(对数秩检验,P<0.001)。
基线25(OH)D与PMN中的肾病蛋白尿及抗PLA2R抗体血清阳性显著相关。作为NR的独立危险因素,随访期间低水平的25(OH)D可能作为一种预后工具,用于敏感地识别治疗反应差可能性高的心衰病例。